Skip to main content

Xavier Montalban Gairín

I am Chair of the Department of Neurology since 2012 and director of the Multiple Sclerosis Center of Catalonia (Cemcat) since 2007 at the Vall d'Hebron University Hospital. I am the head of the Neuroimmunology Research Group at Vall d’Hebron Research Institute (VHIR) since 1995. I am Professor of Neurology at the Autonomous University of Barcelona (UAB) since 2006 and at the University of Vic - Central University of Catalonia (UVic-UCC) since 2021.

Institutions of which they are part

Head of group
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Neurology
General Hospital
Director
Multiple Sclerosis Centre of Catalonia

Xavier Montalban Gairín

Institutions of which they are part

Head of group
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Neurology
General Hospital
Director
Multiple Sclerosis Centre of Catalonia

I am Chair of the Department of Neurology since 2012 and director of the Multiple Sclerosis Center of Catalonia (Cemcat) since 2007 at the Vall d'Hebron University Hospital. I am the head of the Neuroimmunology Research Group at Vall d’Hebron Research Institute (VHIR) since 1995. I am Professor of Neurology at the Autonomous University of Barcelona (UAB) since 2006 and at the University of Vic - Central University of Catalonia (UVic-UCC) since 2021.

I obtained my MD (1983) and PhD (1990) from UAB, and I completed my postgraduate fellowship at St. Thomas' Hospital and the National Hospital for Neurology and Neurosurgery in London. I obtained a Diploma in Comprehensive of Healthcare Institutions Management from ESADE (2005).

In addition to the positions I currently hold, between 2017 and 2020 I served as Professor of Medicine and Director of the Division of Neurology at the University of Toronto and as Director of the MS Center at St Michael's Hospital in the same city.

Since January 2023 I am the chair of the International Advisory Committee on Clinical Trials in Multiple Sclerosis sponsored by ECTRIMS and the National Multiple Sclerosis Society (NMSS), one of the most influential Committee in MS worldwide.

Regarding other leadership roles I am past President (2014-2016) and current Honorary Member of the Council of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). I’m also Board Member of the European Charcot Foundation, as well as serving on numerous local, national and international boards and committees.

My scientific production acrues over 800 scientific papers published in peer-reviewed journals, amounting? more than 52,000 citations and a Scopus H-Index of 101. Over the last consecutive five years I have ranked among the Clarivate most cited researchers.

I have been the Principal Investigator (PI) or Collaborator in more than 35 competitive Projects and have participated as PI in more than 150 clinical trials.

Of Note, I am the recipient of the 2022 John Dystel Prize for MS Research, awarded jointly by the National Multiple Sclerosis Society (NMSS) and the American Academy of Neurology (AAN). I’m the winner of the 2023 Charcot Award granted by the Multiple Sclerosis International Federation (MSIF), which recognises a lifetime of achievement in outstanding research into understanding and treating MS.

Projects

Estudio de los cambios bioquímicos cerebrales mediante espectroscopía por resonancia magnética en la fatiga de los pacientes con esclerosis múltiple.

IP: Jordi Rio Izquierdo
Collaborators: Estudio de los cambios bioquímicos cerebrales mediante espectroscopía por resonancia magnética en la fatiga de los pacientes con, Alex Rovira Cañellas, Xavier Montalban Gairín
Funding agency: Instituto de Salud Carlos III
Funding: 28097.32
Reference: 01/1374
Duration: 17/07/2001 - 31/12/2002

Neutralizing antibodies on Interferon beta in Multiple Sclerosis Contract No 018926

IP: Xavier Montalban Gairín
Collaborators: -
Funding agency: EUROPEAN COMMISSION
Funding: 86400
Reference: FP6-NABINMS-18926
Duration: 01/01/2006 - 30/06/2009

Análisis proteómico en líquido cefaloraquídeo y suero de pacientes con síndromes clínicos aislados sugestivos de esclerosis múltiple

IP: Mar Tintore Subirana
Collaborators: Manuel Comabella Lopez, Xavier Montalban Gairín
Funding agency: Instituto de Salud Carlos III
Funding: 141015
Reference: PI050588
Duration: 01/01/2006 - 31/01/2009

Red Española de Esclerosis Múltiple (perteneciente a la Red CIEN C03/06): Desarrollo de marcadores biológicos y clínicos de la respuesta al tratamiento con Interferón beta en esclerosis múltiple.

IP: Xavier Montalban Gairín
Collaborators: Carlos Nos Llopis, Jordi Rio Izquierdo, Manuel Comabella Lopez, Carmen Espejo Ruiz
Funding agency: Instituto de Salud Carlos III
Funding: 714
Reference: PI052145
Duration: 01/01/2006 - 31/12/2006

Related news

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

Dr. Carmen Espejo and Dr. Georgina Arrambide, researchers at Cemcat and Vall d'Hebron Research Institute, are the first authors of the article.

The research findings propose to modify the McDonald 2017 criteria, only in those in whom diagnosis using the current criteria is not possible.

Related professionals

Joan Piñas Massó

Joan Piñas Massó

Biomedical Research in Cancer Stem Cells
Read more
Gastelum Varela, Graciela

Gastelum Varela, Graciela

Predoctoral researcher
Diabetes and Metabolism
Read more
Francesc Casellas Jordá

Francesc Casellas Jordá

Physiology and Pathophysiology of the Digestive Tract
Read more
Garcia Arabehety, Julia

Garcia Arabehety, Julia

Research technician
Diabetes and Metabolism
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.